Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates.

摘要

We read with great interest the article by Bonomi et al. [1] in which they evaluated the renal toxicity and osteo-necrosis of jaw (ONJ) in 398 cancer patients treated with bisphosphonates (BP). They found that 16 patients (4%) developed renal toxicity after a median of 24 months of BP treatment and 10 patients (2.5%) were diagnosed as having ONJ after a median of 39 months on BP. Concerning the renal safety of intravenous BP, we also want to give information about our study [2] in which we retrospectively evaluated 43 breast cancer patients with bone metastases who received zoledronic acid (ZA) more than 24 months. We also found no statistically significant differences in the pre- and post-treatment levels of serum creatinine, blood urea nitrogen. Our results also support the current study that patients treated with BP showed low incidence of renal toxicity.